ADCC Mediated B-Cell dEpletion and BAFF-R Blockade

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

February 15, 2018

Primary Completion Date

December 28, 2023

Study Completion Date

December 25, 2025

Conditions
Autoimmune Hepatitis
Interventions
BIOLOGICAL

VAY736

VAY736

OTHER

Placebo

Placebo control with conversion to active VAY736

Trial Locations (28)

3010

Novartis Investigative Site, Bern

9000

Novartis Investigative Site, Ghent

12000

Novartis Investigative Site, Vinohrady

20246

Novartis Investigative Site, Hamburg

28009

Novartis Investigative Site, Madrid

28046

Novartis Investigative Site, Madrid

30625

Novartis Investigative Site, Hanover

52074

Novartis Investigative Site, Aachen

55131

Novartis Investigative Site, Mainz

77030

St. Lukes Advanced Liver Therapies, Houston

92118

Southern California Research Center, Coronado

92377

Inland Empire Liver Foundation, Rialto

95817

University of California Davis Medical Center, Sacramento

97080

Novartis Investigative Site, Würzburg

C1056ABJ

Novartis Investigative Site, CABA

C1181ACH

Novartis Investigative Site, CABA

T6G 2B7

Novartis Investigative Site, Edmonton

M5G 2C4

Novartis Investigative Site, Toronto

H2X 1R9

Novartis Investigative Site, Montreal

006-8555

Novartis Investigative Site, Sapporo

760 8557

Novartis Investigative Site, Takamatsu

173 8606

Novartis Investigative Site, Itabashi Ku

08036

Novartis Investigative Site, Barcelona

B15 2TH

Novartis Investigative Site, Birmingham

SE5 9RS

Novartis Investigative Site, London

NE1 4LP

Novartis Investigative Site, Newcastle upon Tyne

NG7 2UH

Novartis Investigative Site, Nottingham

OX3 9DU

Novartis Investigative Site, Oxford

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY